1 Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania.
2 McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Tissue Eng Part A. 2019 Mar;25(5-6):487-498. doi: 10.1089/ten.TEA.2018.0105.
Extracellular matrix (ECM) biomaterials were used to treat esophageal cancer patients after cancer resection and promoted regrowth of normal mucosa without recurrence of cancer. The present study investigates the mechanisms by which these materials were successful to prevent the cancerous phenotype. ECM downregulated neoplastic esophageal cell function (proliferation, metabolism), but normal esophageal epithelial cells were unaffected , and suggests a molecular basis (downregulation of PI3K-Akt, cell cycle) for the promising clinical results. The therapeutic effect appeared to be enhanced using homologous esophageal ECM. This study suggests that ECM can be further investigated to treat cancer patients after resection or in combination with targeted therapy.
细胞外基质(ECM)生物材料被用于治疗癌症切除后的食管癌患者,促进正常黏膜的再生,而无癌症复发。本研究旨在探讨这些材料成功预防癌症表型的机制。ECM 下调了肿瘤性食管细胞的功能(增殖、代谢),但正常食管上皮细胞不受影响,并为有希望的临床结果提供了分子基础(下调 PI3K-Akt、细胞周期)。使用同源食管 ECM 可增强治疗效果。本研究表明,ECM 可进一步研究用于治疗癌症切除后的患者或与靶向治疗联合使用。